• miRagen Therapeutics, Inc. announces collaboration with Servier

    October 18, 2011

    Boulder, CO-based miRagen has racked up its first big collaboration, inking a development pact with France’s Servier for two of its top preclinical programs as well as a third, as yet unidentified, program. In exchange for commercialization rights outside the U.S. and Japan, miRagen gets $45 million in an upfront payment, research support and near-term milestones, up to $352 million in total milestones and double-digit royalties on approved products. Press Release

    Read More
  • CardiaLen, Inc. awarded SBIR Grant

    April 7, 2011

    CardiaLen Awarded Phase I SBIR Grant Cardiac arrhythmia start-up awarded $216,027 grant to develop a novel low-energy system for atrial defibrillation ST. LOUIS (April 7, 2011)—CardiaLen, Inc is pleased to announce that it was notified by the National Heart, Lung, and Blood Institute of a $216,027 Phase I SBIR award to develop an enhanced system for atrial defibrillation (AF). AF is the most frequent arrhythmia in clinical practice and a major contributor to morbidity and mortality. It is estimated that 3 to 5 million Americans are afflicted by atrial fibrillation and are at risk for thr

    Read More
  • CardiaLen, Inc. receives funding from Broadview Ventures

    March 29, 2011

    CardiaLen receives significant financing from Broadview Ventures CardiaLen receives significant financing from Broadview Ventures to complete studies in Atrial Fibrillation March 29, 2011 – CardiaLen, Inc., a medical device company focused on providing pain-free internal cardioversion therapy for atrial fibrillation (AF) with a low-energy implantable atrial cardioverter plus pacing device, received $735,000 in funding from Broadview Ventures, Inc. (broadviewventures.org). The financing will be used as working capital and will help fund the completion of CardiLen’s preclinical animal stud

    Read More
  • CardiAQ Valve Technologies appoints Rob Michiels as CEO

    January 7, 2011

    CardiAQ Valve Technologies (CVT) appoints Rob Michiels as Chief Executive Officer “As former President and COO of CoreValve, Rob Michiels is one of the most experienced executives in percutaneous heart valve implantation.” Arshad Quadri, M.D., CVT Founder, Chairman and Chief Medical officer IRVINE, Calif., Jan. 7, 2011: CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), today announced that it has appointed Rob Michiels, 61, as Chief Executive Officer (CEO), effective

    Read More